ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1022

Association Between Blood Cadmium Level and Kidney Function: Analysis of NHANES 2017-2020

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Wattanachayakul, Phuuwadith, Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States
  • Rujirachun, Pongprueth, Mahidol University Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
  • Lopimpisuth, Chawin, University of Miami Health System, Miami, Florida, United States
  • Lalitnithi, Pakin, St Elizabeth's Medical Center, Brighton, Massachusetts, United States
  • Polpichai, Natchaya, Weiss Memorial Hospital, Chicago, Illinois, United States
  • Tantisattamo, Ekamol, University of California Irvine, Irvine, California, United States

Recent studies have highlighted the significant impact of cadmium toxicity on various organs, including kidneys and the cardiovascular system, whether the association between a wide range of cadmium levels from normal to high toxic levels and kidney function remains unclear.


A cross-sectional study involving participants (≥ 18 years old) in the 2017 - 2020 NHANES was examined by using multiple linear regression analysis for the association between blood cadmium levels (Cd) and kidney function measured by serum creatinine level (SCr).


Of 12,102 participants with Cd results, the mean ± SD age was 37+/-24 years old, and 50.6% were female. White accounts for 33%, followed by Black (25%), Mexican American (13%), and Asian (10%). The Median (IQR) SCr was 0.82 (0.68 - 0.98) mg/dL. We stratified the participants into four quartiles based on their Cd results; the average Cd for each quartile was 0.08, 0.16, 0.29, and 0.93 ug/L, respectively (Figure 1). We found that Q2, Q3, and Q4 participants had significantly higher SCr values of 0.06, 0.08, and 0.14 mg/dL, respectively than those in Q1. (β SCr Q2: 0.06, 95%CI 0.02, 0.09; Q3: 0.08, 95%CI 0.05, 0.12; Q4: 0.14, 95%CI 0.11, 0.17). After adjusting for age, gender, race, BMI, smoking status, high systolic blood pressure (<130 vs.>130 mmHg), diabetic status, and urine albumin creatinine ratio, individuals in the Q3 and Q4 still had significantly higher SCr levels of 0.04 mg/dL. (β SCr Q3: 0.04, 95%CI 0.01,0.07; Q4: 0.04, 95%CI 0.01, 0.07).


Our study found a positive correlation between blood cadmium levels and the risk of declining kidney function, even within the normal range that is not considered toxic. However, future longitudinal studies are required to elucidate this relationship.